Cyprotex held their 5th North American Drug Discovery Workshop on 4th March 2010 at the Embassy Suites San Francisco Airport, South San Francisco, CA.
Cyprotex held a highly successful one day workshop featuring speakers from major pharmaceutical and biotech companies with over 130 attendees mainly from the San Francisco Bay Area drug discovery community.
The speakers and topics were:
Sonia de Morais (Director of DMPK, Abbott Labs) (returning speaker from the Cambridge workshop last year).
'The role of hepatic and renal uptake transporters in drug discovery and development.'
Norman Huebert (Team Leader & Research Fellow ADME, Johnson & Johnson) (returning speaker from the Cambridge workshop last year)
'Research strategies in LG and LO: combining in vitro and in vivo ADME approaches.'
Bernard Murray (Senior Research Scientist I, Gilead)
'Targeted solutions to DMPK problems: avoiding unnecessary screening.'
Ron Aoyama (Senior Scientist I – DMPK. Exelixis)
'Metabolite identification in drug discovery.'
Tim Stratton (Scientist I, ChemoCentryx)
'Drug metabolism in gut microbiota: a case study involving a pyridine N-oxide compound.'
Peng Hsiao (Research Assistant, University of Washington) (we took into account feedback from the Cambridge workshop to include a speaker from academia)
'P-gp based drug interactions at the blood-brain barrier: Fact or fantasy?
Simon Thomas (Head of Scientific Computing, Cyprotex Discovery)
'PBPK modeling for the integration of ADME data during drug discovery.'
Michael Griffin (Principal Scientist, Cyprotex Discovery)
'Comparison of strategies for assessing metabolic stability in vitro.'
Dr Tony Baxter, Chief Executive Officer of Cyprotex introduced and closed the event and commented:
“I am grateful to all the speakers who gave such informative presentations covering key issues in the field of ADME and PK and for providing valuable case studies. I know from the feedback we received on the day and afterwards that our attendees found the day most interesting, instructive and helpful. These events require a lot of organization and I am also grateful to the Cyprotex team who managed the event. We will continue to organize these workshops both in the US and Europe in the future as they help cement Cyprotex’s reputation as ‘thought and opinion leaders’ in pre-clinical drug discovery research and as providers of high quality ADME screening and pharmacokinetic modeling. I look forward to announcing our next workshops being held in the UK in June and on the East Coast in September.”